SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form S-3 - Registration statement under Securities Act of 1933:
SEC Accession No. 0001193125-19-228025
Filing Date
2019-08-23
Accepted
2019-08-23 17:19:30
Documents
8

Document Format Files

Seq Description Document Type Size
1 S-3 d788934ds3.htm S-3 527583
2 EX-1.2 d788934dex12.htm EX-1.2 197062
3 EX-4.4 d788934dex44.htm EX-4.4 283889
4 EX-4.5 d788934dex45.htm EX-4.5 282767
5 EX-5.1 d788934dex51.htm EX-5.1 14356
6 EX-5.2 d788934dex52.htm EX-5.2 7019
7 EX-23.1 d788934dex231.htm EX-23.1 2505
8 GRAPHIC g788934g57j37.jpg GRAPHIC 33539
  Complete submission text file 0001193125-19-228025.txt   1362394
Mailing Address 40 ERIE STREET SUITE 130 CAMBRIDGE MA 02139
Business Address 40 ERIE STREET SUITE 130 CAMBRIDGE MA 02139 857-285-6200
Intellia Therapeutics, Inc. (Filer) CIK: 0001652130 (see all company filings)

IRS No.: 364785571 | State of Incorp.: DE | Fiscal Year End: 1231
Type: S-3 | Act: 33 | File No.: 333-233448 | Film No.: 191049922
SIC: 2835 In Vitro & In Vivo Diagnostic Substances
Office of Life Sciences